Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 12, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| September 11, 2018 | Ordinary Shares (25p each) | £14.9717 | 160 shares (aggregate) | London Stock Exchange (XLON) |
Material Changes
The filing does not report material changes to the company's financial position or operations. It reports routine acquisitions of ordinary shares by ten senior executives under the Company's Share Reward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed as initial notifications for acquisitions of partnership and matching shares.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares under the GSK Share Reward Plan, not open market sales.
- Participants: Transactions involved 10 senior executives, including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and Presidents of Global Vaccines, Global Pharmaceuticals, and Pharmaceutical Supply Chain.
- Volume: The aggregate volume for all executives on September 11, 2018, was 160 shares (typically 16 shares per executive, with one executive acquiring 18 shares).
- Pricing: All shares were acquired at a uniform price of £14.9717.
- Scope: This filing is a regulatory disclosure of insider holdings and does not reflect broader corporate financial performance.